Given that the TGFβ signaling pathway is lost in approximately 30% of colon cancer patients and that IRS-1 has been implicated in the progression of various cancers including colon cancer [16,17,35,36], our study suggests that IRS-1 could be a potential therapeutic target in colon cancer management. The gene discussed is TGFB1; the disease is colonic neoplasm.